

Supplementary data for the article:

Bjelaković, M.; Kop, T.; Maslak, V.; Milić, D. Synthesis and Characterization of Highly Ordered Self-Assembled Bioactive Fulleropeptides. *Journal of Materials Science* **2016**, *51* (2), 739–747. <https://doi.org/10.1007/s10853-015-9396-z>

Electronic Supporting Material

Synthesis and characterization of highly ordered self-assembled bioactive fulleropeptides

Mira Bjelaković¹, Tatjana Kop¹, Veselin Maslak², Dragana Milić^{2*}

¹ICTM-Center for Chemistry, Belgrade, Serbia

²Faculty of Chemistry University of Belgrade, Serbia

* dmilic@chem.bg.ac.rs

Contents:

| | |
|---|-----|
| Procedures for the antioxidant activity determination | S1 |
| Spectral data of compounds 1-12 | S2 |
| Table S1: ¹ H and ¹³ C NMR chemical shifts of the peptide moiety of fullerene acids | S7 |
| IR spectra of compounds 1-11 | S8 |
| ¹ H NMR spectra of compounds 1-12 | S14 |
| ¹³ C NMR spectra of compounds 1-12 | S25 |
| UV spectra of compounds 1-12 | S31 |
| Cyclic voltammograms of compounds 1-12 | S32 |
| Figure S1: SEM images of compounds 2-12 obtained after precipitation with MeOH | S33 |
| Figure S2: SEM images of compounds 2-12 obtained after evaporation from PhMe/MeOH (5/1) mixture | S34 |

Antioxidant activity *in vitro*

FOX reagent preparation [1]

Working FOX reagent was prepared by adding 10 ml of Reagent 1 (98 mg of $(\text{NH}_4)_2\text{Fe}(\text{SO}_4)_2 \times 6\text{H}_2\text{O}$ in 100 ml of 250 mM H_2SO_4) to 900 ml of Reagent 2 (95 mg of Xylenol Orange (XO) Na salt and 880 mg of 2,6-di-t-butyl-4-methylphenol (BHT) in 900 ml of MeOH) giving the final concentrations of 250 μM $(\text{NH}_4)_2\text{Fe}(\text{SO}_4)_2$, 125 μM XO, 25 mM H_2SO_4 , and 4 mM BHT. The complete reagent was used within 24 h or a new batch was made. The absorbance of the Fe^{3+} -XO complex was measured at 560 nm by UV-vis spectroscopy (GBC-Cintra 40) with 90% MeOH as a zero probe.

The procedure includes preparing a standard calibration curve using increasing concentrations (0-200 μM) of TBHP incubated with a FOX reagent at room temperature for 30 min until color formation is complete. 2mM Standard solution of TBHP was prepared by dilution with MeOH.

Standard probe preparation

The standard solution of TBHP was prepared in the same manner without the sample aliquot, which was substituted with H_2O . After incubation the absorbance was determined at 560 nm (A_s).

Blank probe preparation

In all experiments a blank was carried out for determination of the possible activity in the absence of substrate during the incubation period. The blank contained 0.950 ml of FOX reagent and 0.050 ml of H_2O instead of the sample. After incubation the absorbance was determined at 560 nm (A_0).

[1] Gao S, Miller M, Han XQ (2005) Peptide antioxidants from soy protein, EP 1 593 685 A1

Vitamin C, well-known antioxidant, was used as a positive control. The absorbance read at the spectrophotometer for each sample varies in relation to the concentration of TBHP contained in the sample being tested. All analyses were performed in triplicate and average values were taken. The direct antioxidant activity (the percentage of consumed TBHP, Δ) was calculated from the equation

$$\Delta = 100 \times (A - A_s) / (A_s - A_0)$$

where A , A_s , and A_0 represent absorbances of the tested compound, starting (TBHP+FOX), and blank (FOX) probes, respectively. Obtained values are recalculated to the activities relative to the equimolar concentration of vitamin C according to the formula:

$$A_{\text{ox}} \text{ vs vit C} = (\Delta / \Delta_{\text{vit C}}) / (M / M_{\text{vit C}})$$

where Δ and $\Delta_{\text{vit C}}$ represent the direct antioxidant capacity of the tested compound and vitamin C, respectively and M and $M_{\text{vit C}}$ their molecular weights.

Probe preparation

Aliquots of 0.050 mL of prepared solutions of fullerosomes (0.02 mg/mL concentrated), were mixed with the 0.050 mL of the 2mM solution of peroxide and diluted with 0.900 mL of water (corresponds to mixed 0.002mg/mL of sample solution and 200 μ M standard peroxide solution in 1:1 (V/V) ratio). Mixture was than vortexed for 1 min and incubated in stoppered vial at room temperature, for 10 min. From each incubated mixture three aliquots of 0.050 mL were taken and mixed with 0.950 mL of FOX reagent. Absorbance (A) at 560 nm was measured after 80 min of incubation at room temperature, in aim to determine the percentage of consumed peroxide (direct antioxidant activity).

Spectral data of compounds 1-12

Fullerene carbons are labelled as C_f , and pyrrolidinic nuclei as C/H^{pyrr} . The glycine moieties incorporated into the peptide backbones are labelled as Gly¹, Gly² and Gly³ starting from the C terminus. Corresponding GABA-fragments are labelled in the same manner as G, G' and G'' and their atoms are numbered in the order of priority. For the clarity purpose, the example of the hexapeptide **12** with schematic representation of the numbering is given below Table S1 (page S6).

Fp-GABA-OH (Fp-G-OH) **1** (IR, UV and mass spectra were in accordance with the published data [2].

Starting from *tert*-butyl ester (1.19 g, 1.31 mmol) in TFA/DCM (1:1, 40 mL) the acid **1** (1.10 g, 99%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ = 4.4 (CH₂^{pyrr}, overlapped with CD₃OH signal), 3.26 (t, J =7.0 Hz, 2H, CH₂⁴), 2.73 (t, J =7.0 Hz, 2H, CH₂²), 2.31 (quintet, J =7.0 Hz, 2H, CH₂³); ¹H NMR (500 MHz, CDCl₃/CF₃COOD): δ = 5.84 (d, J =12.0 Hz, 2H, CH₂^{pyrr}), 5.07 (d, J =12.0 Hz, 2H, CH₂^{pyrr}), 4.23 (t, J =8.0 Hz, 2H, CH₂⁴), 2.94 (t, J =6.5 Hz, 2H, CH₂²), 2.65 (quintet, J =6.5 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃/CS₂/CF₃COOD): δ =179.81 (COOH), 150.07, 149.75, 148.00, 147.01, 146.91, 146.80, 146.69, 146.43, 146.27, 145.95, 145.91, 145.50, 144.98, 144.87, 144.68, 144.20, 143.33, 143.29, 142.69, 142.55, 142.54, 142.34, 141.93, 141.82, 140.86, 140.84, 136.45, 135.91, 68.00 (C_f-1, 9), 66.04 (CH₂^{pyrr}), 55.39 (CH₂⁴), 30.88 (CH₂²), 20.77 (CH₂³).

Fp-GABA₂-OH (Fp-G'-G-OH) **2**

Starting from *tert*-butyl ester (130 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **2** (120 mg, 99%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ =7.58 (br.t, J =5.0 Hz, 1H, NH^{GABA}), 4.66 (s, 4H, CH₂^{pyrr}), 3.33 (t, J =6.5 Hz, 2H, CH₂⁴), 3.32 (q, J =7.0 Hz, 2H, CH₂⁴), 2.58 (t, J =7.0 Hz, 2H, CH₂²), 2.37 (t, J =7.0 Hz, 2H, CH₂²), 2.30 (quintet, J =7.0 Hz, 2H, CH₂³), 1.87 (quintet, J =7.0 Hz, 2H, CH₂³); ¹³C NMR (125

[2] Bjelakovic MS, Godjevac DM, Milic DR (2007) Synthesis and antioxidant properties of fullero-steroidal covalent conjugates, Carbon 45:2260-2265.

MHz, CDCl₃/CS₂/CD₃OH): δ=175.61 (COOH), 173.62 (CONH), 153.64 (C_f-2, 5, 8, 10), 147.03 (C_f-52, 60), 145.98 (C_f-32, 39, 41, 48), 145.79 (C_f-3, 4, 25, 26), 145.43 (C_f-51, 53, 56, 59), 145.30 (C_f-21, 30), 145.21 (C_f-14, 19, 23, 28), 145.00 (C_f-49, 50, 54, 55), 144.21 (C_f-33, 38, 42, 47), 142.80 (C_f-31, 40), 142.36 (C_f-35, 36, 57, 58), 141.78 (C_f-13, 20, 22, 29), 141.75 (C_f-34, 37, 43, 46), 141.62 (C_f-16, 17, 44, 45), 139.88 (C_f-15, 18, 24, 27), 135.89 (C_f-6, 7, 11, 12), 69.67 (C_f-1, 9), 66.71 (CH₂^{pyrr.}), 53.93 (CH₂⁴), 38.81 (CH₂⁴), 33.63 (CH₂²), 31.30 (CH₂²), 24.31 (CH₂³), 23.55 (CH₂³); IR: ν=3438, 2928, 1672, 1429, 1186, 1137 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ε)=430 (3500), 324 (38000), 305 (37000), 257 nm (98000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₇₀H₁₉N₂O₃: 935.13902 [M+H]⁺, found 935.14058.

Fp-GABA₃-OH(Fp-G''-G'-G-OH) 3

Starting from *tert*-butyl ester (140 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **3** (131 mg, 99%) was obtained. ¹H NMR(500 MHz, CDCl₃/CS₂): δ=7.72 (br.t, *J*=6.0 Hz, 1H, NH^{GABA'}), 7.52 (br.t, *J*=5.5 Hz, 1H, NH^{GABA}), 4.62 (s, 4H, CH₂^{pyrr.}), 3.31 (t, *J*=7.0 Hz, 2H, CH₂^{4''}), 3.27 (q, *J*=7.0 Hz, 2H, CH₂^{4'}), 3.26 (t, *J*=7.0 Hz, 2H, CH₂⁴), 2.57 (t, *J*=7.5 Hz, 2H, CH₂^{2''}), 2.34 (t, *J*=7.0 Hz, 2H, CH₂²), 2.30 (quintet, *J*=7.0 Hz, 2H, CH₂^{3''}), 2.23 (t, *J*=7.5 Hz, 2H, CH₂²), 1.83 (quintet, *J*=7.0 Hz, 2H, CH₂^{3'}), 1.82 (quintet, *J*=7.0 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃): δ=175.71 (COOH), 173.82 (CO^{GABA''}), 173.77 (CO^{GABA'}), 153.85 (C_f-2, 5, 8, 10), 147.09 (C_f-52, 60), 146.03 (C_f-32, 39, 41, 48), 145.84 (C_f-3, 4, 25, 26), 145.53 (C_f-51, 53, 56, 59), 145.37 (C_f-21, 30), 145.25 (C_f-14, 19, 23, 28), 145.06 (C_f-49, 50, 54, 55), 144.28 (C_f-33, 38, 42, 47), 142.86 (C_f-31, 40), 142.41 (C_f-35, 36, 57, 58), 141.83 (C_f-13, 20, 22, 29), 141.83 (C_f-34, 37, 43, 46), 141.68 (C_f-16, 17, 44, 45), 139.93 (C_f-15, 18, 24, 27), 135.95 (C_f-6, 7, 11, 12), 69.83 (C_f-1, 9), 66.91 (CH₂^{pyrr.}), 54.04 (CH₂^{4''}), 38.82, 38.79 (CH₂^{4,4'}), 33.76 (CH₂^{2''}), 33.32 (CH₂²), 31.35 (CH₂²), 25.19 (CH₂^{3'}), 24.23 (CH₂³), 23.83 (CH₂^{3''}); IR: ν=3423, 3306, 3093, 2935, 1648, 1554, 1429, 1186 1137 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ε)=430 (3600), 322 (38000), 304 (37000), 257 nm (110000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₇₄H₂₆N₃O₄: 1020.19178 [M+H]⁺, found 1020.19315.

Fp-GABA-Gly-OH(Fp-G-Gly-OH) 4

Starting from *tert*-butyl ester (125 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **4** (117 mg, 99%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ=7.76 (br.t, *J*=5.5 Hz, 1H, NH^{Gly}), 4.52 (s, 4H, CH₂^{pyrr.}), 3.98 (d, *J*=5.5 Hz, 2H, CH₂^{Gly}), 3.23 (t, *J*=7.0 Hz, 2H, CH₂⁴), 2.64 (t, *J*=7.0 Hz, 2H, CH₂²), 2.28 (quintet, *J*=7.0 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃): δ=173.72 (CONH), 171.31 (COOH), 154.15 (C_f-2, 5, 8, 10), 146.82 (C_f-52, 60), 145.77 (C_f-32, 39, 41, 48), 145.59 (C_f-3, 4, 25, 26), 145.46 (C_f-51, 53, 56, 59), 145.17 (C_f-21, 30), 144.98 (C_f-14, 19, 23, 28), 144.81 (C_f-49, 50, 54, 55), 144.06 (C_f-33, 38, 42, 47), 142.62 (C_f-31, 40), 142.16 (C_f-35, 36, 57, 58), 141.69 (C_f-13, 20, 22, 29), 141.61 (C_f-34, 37, 43, 46), 141.43 (C_f-16, 17, 44, 45), 139.71 (C_f-15, 18, 24, 27), 135.70 (C_f-6, 7, 11, 12), 69.92 (C_f-1, 9), 67.04 (CH₂^{pyrr.}), 53.47 (CH₂⁴), 40.68 (CH₂^{Gly}), 33.20 (CH₂²), 23.78 (CH₂³); IR: ν=3428, 2925, 1656, 1638, 1545, 1187, 1138 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ε)=430 (1900), 324 (16000), 303 (17000), 256 nm (60000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₆₈H₁₅N₂O₃: 907.10772 [M+H]⁺, found 907.10514.

Fp-GABA-Gly₂-OH (Fp-G-Gly²-Gly¹-OH) 5

Starting from *tert*-butyl ester (133 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **5** (124 mg, 99%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ=7.93 (br.t, *J*=5.0 Hz, 1H, NH^{Gly²}), 7.86 (br.t, *J*=5.0 Hz, 1H, NH^{Gly¹}), 4.58 (s, 4H, CH₂^{pyrr.}), 3.95 (d, *J*=5.5 Hz, 2H, CH₂^{Gly²), 3.94 (d, *J*=6.0 Hz, 2H, CH₂^{Gly¹), 3.28 (t, *J*=7.0 Hz, 2H, CH₂⁴), 2.65 (t, *J*=7.0 Hz, 2H, CH₂²), 2.29 (quintet, *J*=7.0 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃/CS₂/CD₃OH): δ=173.92 (CO^{GABA}), 171.19 (COOH), 169.71 (CO^{Gly²}), 153.96 (C_f-2, 5, 8, 10), 146.87 (C_f-52, 60), 145.83 (C_f-32, 39, 41, 48), 145.64 (C_f-3, 4, 25, 26), 145.44 (C_f-51, 53, 56, 59), 145.20 (C_f-21, 30), 145.04 (C_f-14, 19, 23, 28), 144.86 (C_f-49, 50, 54, 55), 144.10 (C_f-33, 38, 42, 47), 142.66 (C_f-31, 40), 142.22 (C_f-35, 36, 57, 58), 141.69 (C_f-13, 20, 22, 29), 141.65 (C_f-34, 37, 43, 46), 141.48 (C_f-16, 17, 44, 45), 139.74 (C_f-15, 18, 24, 27), 135.77 (C_f-6, 7, 11, 12), 69.81 (C_f-1, 9), 66.92 (CH₂^{pyrr.}), 53.71 (CH₂⁴), 42.20 (CH₂^{Gly²), 40.55 (CH₂^{Gly¹), 33.22 (CH₂²), 23.63 (CH₂³); IR: ν=3432, 2926, 1669, 1540, 1423, 1188, 1136, 1032 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ε)=430 (3700), 321 (38000), 305 (39000), 254 nm (110000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₇₀H₁₈N₂O₄: 964.12918 [M+H]⁺, found 964.13113.}}}}

Fp-GABA-Gly₃-OH (Fp-G-Gly³-Gly²-Gly¹-OH) 6

Starting from *tert*-butyl ester (140 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **6** (135 mg, 98%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ=8.09 (br.t, *J*=5.5 Hz, 1H, NH^{Gly3}), 8.06 (br.t, *J*=5.0 Hz, 1H, NH^{Gly2}), 7.91 (br.t, *J*=6.0 Hz, 1H, NH^{Gly1}), 4.60 (s, 4H, CH₂^{pyrr.}), 3.942 (d, *J*=5.5 Hz, 2H, CH₂^{Gly1}), 3.934 (d, *J*=5.5 Hz, 2H, CH₂^{Gly3}), 3.931 (d, *J*=6.0 Hz, 2H, CH₂^{Gly2}), 3.30 (t, *J*=7.0 Hz, 2H, CH₂⁴), 2.66 (t, *J*=7.0 Hz, 2H, CH₂²), 2.30 (quintet, *J*=7.5 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃/CS₂/CD₃OH): δ=174.38 (CO^{GABA}), 171.39 (COOH), 170.10 (CO^{Gly3}), 169.82 (CO^{Gly2}), 153.91 (C_f-2, 5, 8, 10), 146.91 (C_f-52, 60), 145.87 (C_f-32, 39, 41, 48), 145.68 (C_f-3, 4, 25, 26), 145.44 (C_f-51, 53, 56, 59), 145.22 (C_f-21, 30), 145.08 (C_f-14, 19, 23, 28), 144.90 (C_f-49, 50, 54, 55), 144.13 (C_f-33, 38, 42, 47), 142.70 (C_f-31, 40), 142.25 (C_f-35, 36, 57, 58), 141.71 (C_f-13, 20, 22, 29), 141.68 (C_f-34, 37, 43, 46), 141.52 (C_f-16, 17, 44, 45), 139.78 (C_f-15, 18, 24, 27), 135.79 (C_f-6, 7, 11, 12), 69.80 (C_f-1, 9), 66.90 (CH₂^{pyrr.}), 53.75 (CH₂⁴), 42.62 (CH₂^{Gly3}), 42.05 (CH₂^{Gly2}), 40.55 (CH₂^{Gly1}), 33.18 (CH₂²), 23.54 (CH₂³); IR: ν=3407, 2928, 1662, 1543, 1424, 1190, 1136, 1078, 1030 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ε)=430 (3500), 322 (30000), 305 (31000), 257 nm (98000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₇₂H₂₁N₄O₅: 1021.15065 [M+H]⁺, found 1021.15062.

Fp-GABA₂-Gly-OH (Fp-G'-G-Gly-OH) 7

Starting from *tert*-butyl ester (136 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **7** (126 mg, 98%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ=7.76 (br.t, *J*=5.5 Hz, 1H, NH^{Gly}), 7.74 (br.t, *J*=5.5 Hz, 1H, NH^{GABA}), 4.70 (s, 4H, CH₂^{pyrr.}), 3.94 (d, *J*=5.5 Hz, 2H, CH₂^{Gly}), 3.36 (t, *J*=7.5 Hz, 2H, CH₂⁴), 3.31 (q, *J*=6.5 Hz, 2H, CH₂²), 2.56 (t, *J*=7.0 Hz, 2H, CH₂²), 2.31 (t, *J*=7.0 Hz, 2H, CH₂²), 2.30 (quintet, *J*=7.0 Hz, 2H, CH₂³), 1.87 (quintet, *J*=7.0 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃/CS₂/CD₃OH): δ=173.98 (CO^{GABA}), 173.74 (CO^{GABA'}), 171.69 (COOH), 153.50 (C_f-2, 5, 8, 10), 147.04 (C_f-52, 60), 146.00 (C_f-32, 39, 41, 48), 145.80 (C_f-3, 4, 25, 26), 145.39 (C_f-51, 53, 56, 59), 145.31 (C_f-21, 30), 145.23 (C_f-14, 19, 23, 28), 145.02 (C_f-49, 50, 54, 55), 144.22 (C_f-33, 38, 42, 47), 142.81 (C_f-31, 40), 142.37 (C_f-35, 36, 57, 58), 141.79 (C_f-13, 20, 22, 29), 141.73 (C_f-34, 37, 43, 46), 141.64 (C_f-16, 17, 44, 45), 139.89 (C_f-15, 18, 24, 27), 135.93 (C_f-6, 7, 11, 12), 69.58 (C_f-1, 9), 66.61 (CH₂^{pyrr.}), 54.07 (CH₂⁴), 40.87 (CH₂^{Gly}), 38.76 (CH₂⁴), 33.61 (CH₂²), 33.00 (CH₂²), 24.89 (CH₂³), 23.54 (CH₂³); IR: ν=3431, 2924, 2854, 1638, 1544, 1430, 1185, 1134, 1077 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ε)=430 (3700), 323 (30000), 306 (32000), 257 nm (97000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₇₂H₂₂N₃O₄: 992.16048 [M+H]⁺, found 992.16218.

Fp-GABA₂-Gly₂-OH (Fp-G'-G-Gly²-Gly¹-OH) 8

Starting from *tert*-butyl ester (144 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **8** (133 mg, 98%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ=7.92 (br.t, *J*=6.0 Hz, 1H, NH^{Gly2}), 7.85 (br.t, *J*=5.5 Hz, 1H, NH^{Gly1}), 7.68 (br.t, *J*=5.0 Hz, 1H, NH^{GABA}), 4.50 (s, 4H, CH₂^{pyrr.}), 3.95 (d, *J*=5.5 Hz, 2H, CH₂^{Gly1}), 3.91 (d, *J*=5.5 Hz, 2H, CH₂^{Gly2}), 3.29 (q, *J*=6.5 Hz, 2H, CH₂⁴), 3.18 (t, *J*=7.0 Hz, 2H, CH₂⁴), 2.55 (t, *J*=7.0 Hz, 2H, CH₂²), 2.32 (t, *J*=7.0 Hz, 2H, CH₂²), 2.26 (quintet, *J*=7.0 Hz, 2H, CH₂³), 1.86 (quintet, *J*=7.0 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃/CS₂/CD₃OH): δ=174.04 (CO^{GABA}), 173.86 (CO^{GABA'}), 171.47 (CO^{Gly1}), 170.04 (CO^{Gly2}), 154.32 (C_f-2, 5, 8, 10), 146.95 (C_f-52, 60), 145.90 (C_f-32, 39, 41, 48), 145.72 (C_f-3, 4, 25, 26), 145.60 (C_f-51, 53, 56, 59), 145.29 (C_f-21, 30), 145.10 (C_f-14, 19, 23, 28), 144.94 (C_f-49, 50, 54, 55), 144.19 (C_f-33, 38, 42, 47), 142.75 (C_f-31, 40), 142.29 (C_f-35, 36, 57, 58), 141.80 (C_f-13, 20, 22, 29), 141.72 (C_f-34, 37, 43, 46), 141.55 (C_f-16, 17, 44, 45), 139.83 (C_f-15, 18, 24, 27), 135.83 (C_f-6, 7, 11, 12), 70.09 (C_f-1, 9), 67.28 (CH₂^{pyrr.}), 53.92 (CH₂⁴), 42.28 (CH₂^{Gly2}), 40.73 (CH₂^{Gly1}), 38.41 (CH₂⁴), 33.73 (CH₂²), 32.71 (CH₂²), 24.95 (CH₂³), 24.14 (CH₂³); IR: ν=3423, 2924, 1671, 1543, 1428, 1202, 1136 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ε)=430 (3800), 324 (30000), 307 (31000), 259 nm (90000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₇₄H₂₅N₄O₅: 1049.18195 [M+H]⁺, found 1049.18362.

Fp-GABA₂-Gly₃-OH (Fp-G'-G-Gly³-Gly²-Gly¹-OH) 9

Starting from *tert*-butyl ester (151 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **9** (142 mg, 99%) was obtained. ¹H NMR (500 MHz, CDCl₃/CS₂/CD₃OH): δ=8.16 (br.t, *J*=6.0 Hz, 1H, NH^{Gly2}), 8.13 (br.t, *J*=6.0 Hz, 1H, NH^{Gly3}), 7.91 (br.t, *J*=5.5 Hz, 1H, NH^{Gly1}), 7.78 (br.t, *J*=6.0 Hz, 1H, NH^{GABA}), 4.53 (s, 4H, CH₂^{pyrr.}), 3.92 (d, *J*=5.5 Hz, 2H, CH₂^{Gly1}), 3.91 (d, *J*=5.5 Hz, 2H, CH₂^{Gly2}), 3.85 (d, *J*=6.0 Hz, 2H, CH₂^{Gly3}), 3.26 (q, *J*=6.5 Hz, 2H, CH₂⁴), 3.20 (t, *J*=7.0 Hz, 2H, CH₂⁴), 2.54 (t, *J*=7.5 Hz, 2H, CH₂²), 2.31 (t, *J*=7.0 Hz, 2H, CH₂²), 2.25 (quintet, *J*=7.5 Hz, 2H, CH₂³), 1.83 (quintet, *J*=7.0 Hz, 2H, CH₂³); ¹³C NMR (125 MHz, CDCl₃/CS₂/CD₃OH): δ=174.42 (CO^{GABA}), 173.79 (CO^{GABA'}), 171.35 (CO^{Gly1}), 170.26 (CO^{Gly3}), 169.92 (CO^{Gly2}), 154.11 (C_f-2, 5, 8, 10), 146.85 (C_f-52, 60), 145.80 (C_f-32, 39, 41, 48), 145.62 (C_f-3, 4, 25, 26),

145.46 (C_f -51, 53, 56, 59), 145.18 (C_f -21, 30), 145.01 (C_f -14, 19, 23, 28), 144.84 (C_f -49, 50, 54, 55), 144.09 (C_f -33, 38, 42, 47), 142.65 (C_f -31, 40), 142.19 (C_f -35, 36, 57, 58), 141.68 (C_f -13, 20, 22, 29), 141.63 (C_f -34, 37, 43, 46), 141.46 (C_f -16, 17, 44, 45), 139.73 (C_f -15, 18, 24, 27), 135.74 (C_f -6, 7, 11, 12), 69.91 (C_f -1, 9), 67.09 (CH_2^{pyr}), 53.88 (CH_2^4), 42.54 ($CH_2^{Gly^3}$), 41.98 ($CH_2^{Gly^2}$), 40.46 ($CH_2^{Gly^1}$), 38.23 (CH_2^4), 33.58 (CH_2^2), 32.36 (CH_2^2), 24.77 (CH_2^3), 24.04 (CH_2^3); IR: ν =3426, 2926, 1655, 1544, 1427, 1186, 1135, 1078 cm^{-1} ; UV/Vis ($CHCl_3$): λ_{max} (ϵ)=430 (3000), 323 (27000), 305 (28000), 256 nm (90000 $mol^{-1}dm^3cm^{-1}$); ESI-TOF-MS: m/z : calcd for $C_{76}H_{28}N_5O_6$: 1106.20341 [$M+H$]⁺, found 1106.20491.

Fp-GABA₃-Gly-OH (Fp-G''-G'-G-Gly-OH) 10

Starting from *tert*-butyl ester (147 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **10** (138 mg, 99 %) was obtained. ¹H NMR (500 MHz, $CDCl_3/CS_2/CD_3OH$): δ =7.79 (br.t, J =5.5 Hz, 1H, NH^{Gly}), 7.72 (br.t, J =5.5 Hz, 1H, $NH^{GABA'}$), 7.70 (br.t, J =5.5 Hz, 1H, NH^{GABA}), 4.57 (s, 4H, CH_2^{pyr}), 3.93 (d, J =5.5 Hz, 2H, CH_2^{Gly}), 3.26 (q, J =6.0 Hz, 2H, CH_2^4), 3.25 (t, J =6.0 Hz, 2H, CH_2^4), 3.24 (q, J =6.5 Hz, 2H, CH_2^4), 2.56 (t, J =7.5 Hz, 2H, CH_2^2), 2.28 (quintet, J =6.5 Hz, 4H, CH_2^2 , CH_2^3), 2.22t (t, J =7.0 Hz, 2H, CH_2^2), 1.82 (quintet, J =6.5 Hz, 4H, $CH_2^{3,3'}$); ¹³C NMR (125 MHz, $CDCl_3/CS_2/CD_3OH$): δ =173.97 (CO^{GABA}), 173.86 ($CO^{GABA''}$), 173.82 ($CO^{GABA'}$), 171.70 (CO^{Gly}), 154.02 (C_f -2, 5, 8, 10), 147.01 (C_f -52, 60), 145.96 (C_f -32, 39, 41, 48), 145.77 (C_f -3, 4, 25, 26), 145.54 (C_f -51, 53, 56, 59), 145.32 (C_f -21, 30), 145.17 (C_f -14, 19, 23, 28), 144.99 (C_f -49, 50, 54, 55), 144.22 (C_f -33, 38, 42, 47), 142.80 (C_f -31, 40), 142.35 (C_f -35, 36, 57, 58), 141.80 (C_f -13, 20, 22, 29), 141.77 (C_f -34, 37, 43, 46), 141.61 (C_f -16, 17, 44, 45), 139.87 (C_f -15, 18, 24, 27), 135.88 (C_f -6, 7, 11, 12), 69.92 (C_f -1, 9), 67.06 (CH_2^{pyr}), 53.99 (CH_2^4), 40.84 (CH_2^{Gly}), 38.70 (CH_2^4), 38.54 (CH_2^4), 33.75 (CH_2^2), 33.18 (CH_2^2), 32.97 (CH_2^2), 25.14 (CH_2^3), 24.86 (CH_2^3), 23.97 (CH_2^3); IR: ν =3427, 2928, 1646, 1544, 1430, 1187, 1136, 1077 cm^{-1} ; UV/Vis ($CHCl_3$): λ_{max} (ϵ)=430 (3500), 323 (33000), 306 (35000), 258 nm (99000 $mol^{-1}dm^3cm^{-1}$); ESI-TOF-MS: m/z : calcd for $C_{76}H_{29}N_4O_5$: 1077.21325 [$M+H$]⁺, found 1077.21457.

Fp-GABA₃-Gly₂-OH (Fp-G''-G'-G-Gly²-Gly¹-OH) 11

Starting from *tert*-butyl ester (155 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **11** (146 mg, 99%) was obtained. ¹H NMR (500 MHz, $CDCl_3/CS_2/CD_3OH$): δ =7.92 (br.t, J =5.5 Hz, 1H, NH^{Gly^2}), 7.86 (br.t, J =5.5 Hz, 1H, NH^{Gly^1}), 7.74 (br.t, 1H, J =6.0 Hz, $NH^{GABA'}$), 7.69 (br.t, J =6.0 Hz, 1H, NH^{GABA}), 4.64 (s, 4H, CH_2^{pyr}), 3.95 (d, J =5.5 Hz, 2H, $CH_2^{Gly^1}$), 3.90 (d, J =6.0 Hz, 2H, $CH_2^{Gly^2}$), 3.31 (t, J =7.5 Hz, 2H, CH_2^4), 3.25 (q, J =7.0 Hz, 2H, CH_2^4), 3.23 (q, J =6.0 Hz, 2H, CH_2^4), 2.56 (t, J =7.0 Hz, 2H, CH_2^2), 2.29 (quintet, J =7.0 Hz, 4H, CH_2^2 , CH_2^3), 2.22 (t, J =7.5 Hz, 2H, CH_2^2), 1.82 and 1.81 (2 quintets, 4H, $CH_2^{3,3'}$); ¹³C NMR (125 MHz, $CDCl_3/CS_2/CD_3OH$): δ =173.99 (CO^{GABA}), 173.80 ($CO^{GABA''}$), 173.78 ($CO^{GABA'}$), 171.48 (CO^{Gly^1}), 170.12 (CO^{Gly^2}), 153.75 (C_f -2, 5, 8, 10), 147.02 (C_f -52, 60), 145.97 (C_f -32, 39, 41, 48), 145.78 (C_f -3, 4, 25, 26), 145.45 (C_f -51, 53, 56, 59), 145.30 (C_f -21, 30), 145.19 (C_f -14, 19, 23, 28), 145.00 (C_f -49, 50, 54, 55), 144.21 (C_f -33, 38, 42, 47), 142.80 (C_f -31, 40), 142.36 (C_f -35, 36, 57, 58), 141.77 (C_f -13, 20, 22, 29), 141.75 (C_f -34, 37, 43, 46), 141.61 (C_f -16, 17, 44, 45), 139.87 (C_f -15, 18, 24, 27), 135.89 (C_f -6, 7, 11, 12), 69.74 (C_f -1, 9), 66.83 (CH_2^{pyr}), 54.02 (CH_2^4), 42.34 ($CH_2^{Gly^2}$), 40.77 ($CH_2^{Gly^1}$), 38.69 (CH_2^4), 38.24 (CH_2^4), 33.66 (CH_2^2), 33.07 (CH_2^2), 32.62 (CH_2^2), 25.06 (CH_2^3), 24.80 (CH_2^3), 23.77 (CH_2^3); IR: ν =3291, 3089, 2934, 1650, 1547, 1428, 1196, 1136, 1079 cm^{-1} ; UV/Vis ($CHCl_3$): λ_{max} (ϵ)=430 (3000), 319 (28000), 306 (29000), 257 nm (91000 $mol^{-1}dm^3cm^{-1}$); ESI-TOF-MS: m/z : calcd for $C_{78}H_{32}N_4O_6$: 1134.23471 [$M+H$]⁺, found 1134.23570.

Fp-GABA₃-Gly₃-OH (Fp-G''-G'-G-Gly³-Gly²-Gly¹-OH) 12


Starting from *tert*-butyl ester (162 mg, 0.13 mmol) in TFA/DCM (1:1, 4 mL) the acid **12** (154 mg, 100%) was obtained. ¹H NMR (500 MHz, $CDCl_3/CS_2/CD_3OH$): δ =8.19 (br.t, J =6.0 Hz, 1H, NH^{Gly^2}), 8.12 (br.t, J =6.0 Hz, 1H, NH^{Gly^3}), 7.88 (br.t, J =5.5 Hz, 1H, NH^{Gly^1}), 7.81 (br.t, 1H, J =5.5 Hz, $NH^{GABA'}$), 7.71 (br.t, J =5.5 Hz, 1H, NH^{GABA}), 4.63 (s, 4H, CH_2^{pyr}), 3.93 (d, J =5.5 Hz, 2H, $CH_2^{Gly^1}$), 3.92 (d, J =5.0 Hz, 2H, $CH_2^{Gly^2}$), 3.86 (d, J =5.5 Hz, 2H, $CH_2^{Gly^3}$), 3.30 (t, J =7.5 Hz, 2H, CH_2^4), 3.25 (q, J =6.5 Hz, 2H, CH_2^4), 3.22 (q, J =6.5 Hz, 2H, CH_2^4), 2.57 (t, J =7.0 Hz, 2H, CH_2^2), 2.29 (t, J =7.0 Hz, 2H, CH_2^2), 2.28 (qui., 2H, CH_2^3), 2.22 (t, J =7.5 Hz, 2H, CH_2^2), 1.81 (qui., J =6.5 Hz, 2H, CH_2^3), 1.80 (qui., J =6.5 Hz, 2H, CH_2^3); ¹³C NMR (125 MHz, $CDCl_3/CS_2/CD_3OH$): δ =174.50 (CO^{GABA}), 173.82 ($CO^{GABA''}$), 173.80 ($CO^{GABA'}$), 171.42 (CO^{Gly^1}), 170.43 (CO^{Gly^3}), 170.07 (CO^{Gly^2}), 153.74 (C_f -2, 5, 8, 10), 146.97 (C_f -52, 60), 145.92 (C_f -32, 39, 41, 48), 145.73 (C_f -3, 4, 25, 26), 145.41 (C_f -51, 53, 56, 59), 145.25 (C_f -21, 30), 145.14 (C_f -14, 19, 23, 28), 144.95 (C_f -49, 50, 54, 55), 144.16 (C_f -33, 38, 42, 47), 142.76 (C_f -31, 40), 142.31 (C_f -35, 36, 57, 58), 141.72 (C_f -13,

20, 22, 29), 141.71 (C_f-34, 37, 43, 46), 141.56 (C_f-16, 17, 44, 45), 139.82 (C_f-15, 18, 24, 27), 135.85 (C_f-6, 7, 11, 12), 69.72 (C_f-1, 9), 66.82 (CH₂^{pyrr.}), 54.00 (CH₂^{4"}), 42.74 (CH₂^{Gly³}), 42.15 (CH₂^{Gly²}), 40.60 (CH₂^{Gly¹}), 38.63 (CH₂^{4'}), 38.04 (CH₂⁴), 33.63 (CH₂^{2"}), 32.99 (CH₂^{2'}), 32.24 (CH₂²), 25.05 (CH₂^{3'}), 24.70 (CH₂³), 23.76 (CH₂^{3"}); IR: ν =3416, 2929, 1651, 1546, 1426, 1188, 1135, 1078 cm⁻¹; UV/Vis (CHCl₃): λ_{max} (ϵ)=430 (3600), 321 (31000), 305 (32000), 257 nm (105000 mol⁻¹dm³cm⁻¹); ESI-TOF-MS: *m/z*: calcd for C₈₀H₃₅N₆O₇: 1191.25617 [M+H]⁺, found 1191.25671.

Table S1 ^1H and ^{13}C NMR chemical shifts of the peptide moiety of fullerene acids


| $^{13}\text{C}/^1\text{H}$ | FpG | FpG ₂ | FpG ₃ | FpGGly | FpGGly ₂ | FpGGly ₃ | FpG ₂ Gly | FpG ₂ Gly ₂ | FpG ₂ Gly ₃ | FpG ₃ Gly | FpG ₃ Gly ₂ | FpG ₃ Gly ₃ |
|-------------------------------------|------------------|------------------|------------------|------------------|---------------------|---------------------|----------------------|-----------------------------------|-----------------------------------|----------------------|-----------------------------------|-----------------------------------|
| CO(1) | 179.81 | 175.61 | 175.71 | 173.72 | 173.92 | 174.38 | 173.98 | 174.04 | 174.42 | 173.97 | 173.99 | 174.50 |
| CO(1') | | 173.62 | 173.77 | | | | 173.74 | 173.86 | 173.79 | 173.82 | 173.78 | 173.80 |
| CO(1'') | | | 173.82 | | | | | | | 173.86 | 173.80 | 173.82 |
| CH ₂ (2) | 30.88 2.73t | 31.30 2.37t | 31.35 2.34t | 33.20 2.64t | 33.22 2.65t | 33.18 2.66t | 33.00 2.31t | 32.71 2.32t | 32.36 2.31t | 32.97 2.28t | 32.62 2.29t | 32.24 2.289t |
| CH ₂ (2'') | | 33.63 2.58t | 33.32 2.23t | | | | 33.61 2.56t | 33.73 2.55t | 33.58 2.54t | 33.18 2.22t | 33.07 2.12t | 32.99 2.22t |
| CH ₂ (2'') | | | 33.76 2.57t | | | | | | | 33.75 2.56t | 33.66 2.56t | 33.63 2.57t |
| CH ₂ (3) | 20.77 2.31qui | 24.31 1.87qui | 24.23 1.82qui | 23.78 2.28qui | 23.63 2.29qui | 23.54 2.30qui | 24.89 1.87qui | 24.95 1.86qui | 24.77 1.83qui | 24.86 1.82qui | 24.80 1.82qui | 24.70 1.80qui |
| CH ₂ (3'') | | 23.55 2.30qui | 25.19 1.83qui | | | | 23.54 2.30qui | 24.14 2.26qui | 24.04 2.25qui | 25.14 1.82qui | 25.06 1.81qui | 25.05 1.81qui |
| CH ₂ (3'') | | | 23.83 2.30qui | | | | | | | 23.97 2.28qui | 23.77 2.29qui | 23.76 2.285qui |
| CH ₂ (4) | 55.39 3.26t | 38.81 3.32q | 38.82 3.26q | 53.47 3.23t | 53.71 3.28t | 53.75 3.30t | 38.76 3.31q | 38.41 3.29q | 38.23 3.26q | 38.54 3.24q | 38.24 3.23q | 38.04 3.22q |
| CH ₂ (4'') | | 53.93 3.33t | 38.79 3.27q | | | | 54.07 3.36t | 53.92 3.18t | 53.88 3.20t | 38.70 3.26q | 38.69 3.25q | 38.63 3.25q |
| CH ₂ (4'') | | | 54.04 3.31t | | | | | | | 53.99 3.25t | 54.02 3.31t | 54.00 3.30t |
| CH ₂ (Gly ¹) | | | | 40.68 3.98d | 40.55 3.94d | 40.55 3.942d | 40.87 3.94d | 40.73 3.95d | 40.46 3.92d | 40.84 3.93d | 40.77 3.95d | 40.60 3.93d |
| CH ₂ (Gly ²) | | | | | 42.20 3.95d | 42.05 3.931d | | 42.28 3.91d | 41.98 3.91d | | 42.34 3.90d | 42.15 3.92d |
| CH ₂ (Gly ³) | | | | | | 42.62 3.934d | | | 42.54 3.85d | | | 42.74 3.86d |
| CO(Gly ¹) | | | 171.31 | 171.19 | 171.39 | 171.69 | 171.47 | 171.35 | 171.70 | 171.48 | 171.42 | |
| CO(Gly ²) | | | | 169.71 | 169.82 | | 170.04 | 169.92 | | 170.12 | 170.07 | |
| CO(Gly ³) | | | | | 170.10 | | | 170.26 | | | 170.43 | |
| NH(G) | 7.58br.t | 7.52br.t | | | | 7.74br.t | 7.68br.t | 7.78br.t | 7.70br.t | 7.69br.t | 7.71br.t | |
| NH(G') | | 7.72br.t | | | | | | | 7.72br.t | 7.74br.t | 7.81br.t | |
| NH(Gly ¹) | | | 7.76br.t | 7.86br.t | 7.91br.t | 7.76br.t | 7.85br.t | 7.91br.t | 7.79br.s | 7.86br.t | 7.88br.t | |
| NH(Gly ²) | | | | 7.93br.t | 8.06br.t | | 7.92br.t | 8.16br.t | | 7.92br.t | 8.19br.t | |
| NH(Gly ³) | | | | | 8.09br.t | | | 8.13br.t | | | 8.12br.t | |

qui = quintet


FpG₃Gly₃

IR spectra of compounds 1-12


1: Fp-GABA-OH




2: Fp-GABA-GABA-OH





3: Fp-GABA-GABA-GABA-OH




4: Fp-GABA-Gly-OH







7: Fp-GABA-GABA-Gly-OH




8: Fp-GABA-GABA-Gly-Gly-OH




9; Fp-GABA-GABA-Gly-Gly-OH




10; Fp-GABA-GABA-GABA-Gly-OH




11: Fp-GABA-GABA-GABA-Gly-Gly-OH





12: Fp-GABA-GABA-GABA-Gly-Gly-Gly-OH





¹H NMR spectra of compounds 1-12






























¹³C NMR spectra of 1-12



```

NAME      MBF-6K
EXPNO
PSCNCHD    1
Date     20100709
Time      11.41
INSTRNMNT spect
BOND      5 mm BBO-1B
PULPROG  zpgp30
TD        32768
SOLVENT   D2O
NS        4000
DS         4
SWH      29716.904 Hz
FIDRES   0.908261 Hz
AQ        0.5505524 sec
RG        100.0
DW        16,000 usec
DE        6.50 usec
TE        298.0 K
D1        2.0000000 sec
O1        0.03000000 sec
T001

```

```
===== CHANNEL f1 =====
NUC1           13C
P1            11.50 used
PLL           3.00 dB
PLI1W         32.22848892 W
SFO1        125.8043140 MHZ
```

```

CHANNEL f2 =====
CPDPRG2      ztwt16
NUC2          1H
FCPFD2      80.00 usec
PLA          1.20 dB
PL12         15.40 dB
PL13         16.00 dB
PL24         20.76592171 W
PL12W        0.39575511 W
PL13W        0.39575511 W
SFZD2       500.2617344 MHz
SI           32768
SF          125.7901145 MHz
MMW          EM
SSB          0
LB          1.50 Hz
GB          0
PC          1.40

```

1


```

NAME MBF-59K
EXPNO 6
PROCNO 1
DATE 20100713
TIME 10.29
INSTRUM spect
PROBHD 5 mm BBO BB=1H
PULPROG zpg300
TD 32768
SOLVENT CDCl3
NS 15918
DS 8
SWH 29761.904 Hz
TB 0.908261
AQ 0.5505524 sec
RG 2050
DW 16.000 usec
DE 6.50 usec
TE 298.0 K
D1 2.00000000 sec
D11 0.03000000 sec
DW1 0.25000000 sec


```


===== CHANNEL f1 =====
NUC1 13C
P1 11.50 use
PLL 3.00 dB
PLIw 32.22848892 W
SF01 125.8043140 MHz


| | CHANNEL F2 | waltzie |
|----------|-------------|---------|
| CPDP0RG2 | | |
| MWC2 | | 0.00 |
| FCPD22 | 80.00 | use |
| PL2 | 1.20 | dB |
| PL12 | 18.40 | dB |
| PL13 | 18.40 | dB |
| PL2W | 20.76952171 | W |
| PL12W | 0.39575511 | W |
| PL13W | 0.39575511 | W |
| SFO2 | 500.2618590 | MHz |
| ST | 32768 | |
| SP | 125.7905028 | MHz |
| NDW | | |
| SSB | 0 | |
| LB | 1.50 | Hz |
| GB | 0 | |
| FC | 1.40 | |





2













UV spectra of compounds 1-12

Cyclic voltammograms of compounds 1-12






Figure S1 SEM images of fulleropeptide acids **2-12** deposited on a brass substrate after precipitation with MeOH




Figure S2 SEM images of compounds **2-12** prepared from PhMe/MeOH (5/1, v/v) mixture on a Si substrate upon evaporation of 10 µL of 1mM solution at room temperature; inset on **3**: 10 µL of 0.1mM solution; **9** and **10**, right, 30 µL of 1mM solution.